Compare Stocks: BNTC, BCAX, IMCR, and SNDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$27.99 -0.2%	$25.68	$9.57 ▼ $30.99	$1.84B	-0.75	593,568 shs	28,634 shs
BNTC Benitec Biopharma	$13.52 -0.8%	$12.16	$9.85 ▼ $16.76	$464.45M	0.28	129,219 shs	6,506 shs
IMCR Immunocore	$33.67 -1.0%	$31.64	$27.56 ▼ $40.71	$1.72B	0.74	466,887 shs	14,052 shs
SNDX Syndax Pharmaceuticals	$20.21 -0.9%	$20.43	$12.10 ▼ $25.59	$1.79B	0.4	1.62 million shs	59,856 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	+3.54%	-2.94%	+22.43%	+175.10%
BNTC Benitec Biopharma	0.00%	+16.40%	+1.56%	+12.83%	+15.51%
IMCR Immunocore	0.00%	+0.56%	+6.42%	+17.85%	+6.35%
SNDX Syndax Pharmaceuticals	0.00%	+7.09%	-13.60%	-4.58%	+63.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$27.99 -0.2%	$25.68	$9.57 ▼ $30.99	$1.84B	-0.75	593,568 shs	28,634 shs
BNTC Benitec Biopharma	$13.52 -0.8%	$12.16	$9.85 ▼ $16.76	$464.45M	0.28	129,219 shs	6,506 shs
IMCR Immunocore	$33.67 -1.0%	$31.64	$27.56 ▼ $40.71	$1.72B	0.74	466,887 shs	14,052 shs
SNDX Syndax Pharmaceuticals	$20.21 -0.9%	$20.43	$12.10 ▼ $25.59	$1.79B	0.4	1.62 million shs	59,856 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	+3.54%	-2.94%	+22.43%	+175.10%
BNTC Benitec Biopharma	0.00%	+16.40%	+1.56%	+12.83%	+15.51%
IMCR Immunocore	0.00%	+0.56%	+6.42%	+17.85%	+6.35%
SNDX Syndax Pharmaceuticals	0.00%	+7.09%	-13.60%	-4.58%	+63.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.73	Moderate Buy	$30.27	8.16% Upside
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	83.43% Upside
IMCR Immunocore	2.55	Moderate Buy	$57.29	70.16% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$42.36	109.62% Upside

Current Analyst Ratings Breakdown

Latest BNTC, BCAX, IMCR, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
8/3/2026	IMCR Immunocore	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$34.00 ➝ $35.00
7/28/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IMCR Immunocore	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
IMCR Immunocore	$400.02M	4.28	N/A	N/A	$7.52 per share	4.48
SNDX Syndax Pharmaceuticals	$172.35M	10.39	N/A	N/A	$0.74 per share	27.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$2.78	N/A	N/A	N/A	N/A	-35.89%	-33.78%	8/11/2026 (Estimated)
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	73.18	N/A	-4.20%	-4.54%	-1.66%	N/A
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	N/A

Latest BNTC, BCAX, IMCR, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.58 million	$115.93 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million
5/14/2026	Q3 2026	BNTC Benitec Biopharma	-$0.27	-$0.24	+$0.03	-$0.24	$4.55 million	N/A
5/11/2026	Q1 2026	BCAX Bicara Therapeutics	-$0.72	-$0.93	-$0.21	-$0.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	13.85	13.85
BNTC Benitec Biopharma	N/A	56.82	56.82
IMCR Immunocore	0.94	4.47	4.44
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
BNTC Benitec Biopharma	52.19%
IMCR Immunocore	84.50%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
BNTC Benitec Biopharma	4.80%
IMCR Immunocore	10.10%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	65.70 million	56.64 million	N/A
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
IMCR Immunocore	320	50.87 million	45.73 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable

BNTC, BCAX, IMCR, and SNDX Headlines

Recent News About These Companies

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 9 at 6:07 AM | marketbeat.com

Q3 EPS Forecast for Syndax Pharmaceuticals Cut by Analyst

August 9 at 1:14 AM | americanbankingnews.com

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors

August 8 at 2:01 PM | finance.yahoo.com

Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX

August 8 at 3:44 AM | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for SNDX

August 7 at 6:11 AM | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 7 at 3:05 AM | americanbankingnews.com

What is HC Wainwright's Estimate for SNDX FY2029 Earnings?

August 6, 2026 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Syndax Pharmaceuticals (SNDX) Q2 2026

August 5, 2026 | 247wallst.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings

August 5, 2026 | marketbeat.com

HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 5, 2026 | marketbeat.com

Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX

August 5, 2026 | marketbeat.com

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Syndax: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Syndax Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2026 | zacks.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results

August 4, 2026 | marketbeat.com

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

August 4, 2026 | globenewswire.com

Syndax Pharmaceuticals (SNDX) Projected to Post Quarterly Earnings on Tuesday

August 3, 2026 | americanbankingnews.com

Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, BCAX, IMCR, and SNDX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$27.99 -0.07 (-0.25%)

As of 10:20 AM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$13.52 -0.11 (-0.81%)

As of 10:18 AM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Immunocore NASDAQ:IMCR

$33.66 -0.34 (-0.99%)

As of 10:19 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Syndax Pharmaceuticals NASDAQ:SNDX

$20.21 -0.19 (-0.93%)

As of 10:03 AM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, BCAX, IMCR, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, BCAX, IMCR, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, BCAX, IMCR, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, BCAX, IMCR, and SNDX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Benitec Biopharma NASDAQ:BNTC

Immunocore NASDAQ:IMCR

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNTC, BCAX, IMCR, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNTC, BCAX, IMCR, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNTC, BCAX, IMCR, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, BCAX, IMCR, and SNDX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Benitec Biopharma NASDAQ:BNTC

Immunocore NASDAQ:IMCR

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools